{
  "hash": "aa2a5d24cc01c5bbf5159c7cfe37f396",
  "result": {
    "engine": "knitr",
    "markdown": "---\ntitle: An introduction to EBM (session 5)\ndate: 2024-09-09\nexecute: \n  echo: false\n  eval: true\n  freeze: auto\n  output: \"markup\"\ncategories: [skills, beginner, evidence-based medicine, critical appraisal, clinical trials]\nbibliography: src/references.bib\neditor_options: \n  chunk_output_type: console\n---\n\n\n## Session outline\n\n+ this session is all about what happens **beyond the RCT**?\n+ we'll recap some of the issues we discussed last time as motivation\n+ then we'll introduce and discuss a pair of ways of summarising multiple RCTs\n+ we'll relate these two methods back to our earlier discussions about bias\n+ and we'll look at a totally different way of solving some of the problems of RCTs\n\n## Recap\n\n+ detecting treatment effects is hard\n    + effects are subtle\n    + trials have practical problems (like recruitment)\n+ studies are often underpowered\n    + so they fail to find a real treatment effect\n+ that causes harm\n    + some valuable treatments get ignored\n    + some harmful treatments remain in use\n\n# systematic review\n\n## E1: the logo\n\n::: {.callout-tip title=\"Task\"}\n\n1. Please visit [https://www.cochrane.org/](https://www.cochrane.org/)\n1. Two questions for the chat:\n    1. What does Cochrane do?\n    1. What does their logo show?\n\n:::\n\n\n## Cochrane story\n\n\n::: {.cell TRUE='true'}\n::: {.cell-output-display}\n\n\nTable: Data from randomised trials before 1980 of corticosteroid therapy in premature labour and its effect on neonatal death.\n\n|Identifier   | Deaths (Treatment)| n (Treatment)| Deaths (Control)| n (Control)|\n|:------------|------------------:|-------------:|----------------:|-----------:|\n|Auckland     |                 36|           532|               60|         538|\n|Block        |                  1|            69|                5|          61|\n|Doran        |                  4|            81|               11|          63|\n|Gamsu        |                 14|           131|               20|         137|\n|Morrison     |                  3|            67|                7|          59|\n|Papageorgiou |                  1|            71|                7|          75|\n|Tauesch      |                  8|            56|               10|          71|\n\n\n:::\n:::\n\n\n## Cochrane story\n\n\n::: {.cell}\n::: {.cell-output-display}\n![](ebm_05_files/figure-html/unnamed-chunk-2-1.png){width=672}\n:::\n:::\n\n\n## Forest plots\n\n::: columns\n\n:::: {.column width=\"50%\"}\n\n\n::: {.cell}\n::: {.cell-output-display}\n![](ebm_05_files/figure-html/unnamed-chunk-3-1.png){width=672}\n:::\n:::\n\n::::\n\n:::: {.column width=\"50%\"}\n\n+ [useful intro](https://uk.cochrane.org/news/how-read-forest-plot)\n+ one row per study\n+ box size corresponds with study size (weight)\n+ box location corresponds with odds ratio (OR)\n+ whiskers (horizonal lines) showing the confidence interval of that OR\n+ pooled effect show by the diamond\n    + size = total weight\n    + horizontal limits = confidence interval\n\n\n::: {.notes}\n\n1. how would you interpret the line representing a study crossing 1?\n1. how can individual lines cross 1, but the pooled diamond not cross 1?\n\n:::\n\n::::\n\n:::\n\n\n\n## E2: from 1982 to 2020\n\n::: {.callout-tip title=\"Task\"}\n\n1. Find the [current version of this Cochrane review](https://www.cochrane.org/news/featured-review-antenatal-corticosteroids-accelerating-fetal-lung-maturation-women-risk-preterm)\n1. What are the main current recommendations?\n\n\n:::\n\n## Current recommendations\n\n\n::: {.cell}\n::: {.cell-output-display}\n![](https://www.cochrane.org/sites/default/files/public/uploads/cd004454_antenatal_corticosteroids1.png)\n:::\n:::\n\n## Cochrane reviews are systematic reviews\n\n> A systematic review attempts to identify, appraise and synthesize all the empirical evidence that meets pre-specified eligibility criteria to answer a specific research question ([Cochrane library](https://www.cochranelibrary.com/about/about-cochrane-reviews))\n\n## Explicit strategies\n+ like EBM itself\n+ e.g. Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([PRISMA](http://www.prisma-statement.org/))\n\n\n::: {.cell}\n::: {.cell-output-display}\n![](https://raw.githubusercontent.com/nealhaddaway/PRISMA2020/master/inst/extdata/PRISMA.png)\n:::\n:::\n\n\n# Meta-analysis\n\n## What's the difference?\n\n+ systematic reviews attempt to include **all** the relevant studies\n+ meta-analyses include **some** relevant studies\n+ that might give rise to biases...\n\n### E3: bias and MA/SR\n\n::: {.callout-tip title=\"Task\"}\n\n1. [Some authors](https://training.cochrane.org/handbook/current/chapter-07) argue that systematic reviews should generally be preferred to meta-analyses on the ground of bias. Can you think of biases that might affect MA, but not SR?\n1. Can you think of different reasons why you might prefer a MA, rather than a SR?\n\n:::\n\n\n## Bad pharma\n\n::: columns\n\n:::: {.column width=\"30%\"}\n\n::: {.cell}\n::: {.cell-output-display}\n![](https://upload.wikimedia.org/wikipedia/en/7/7a/Bad_Pharma.jpg)\n:::\n:::\n\n::::\n\n:::: {.column width=\"70%\"}\n+ undue influence of industry on drug research\n+ **plus**\n+ excessive emphasis on the methods of trials, rather than their conduct\n+ **plus**\n+ pressure to perform larger, cleaner, RCTs \n+ **produces**\n+ a \"murderous disaster\" [@goldacre2012]\n\n::::\n\n:::\n\n\n# Two kinds of validity\n\n## Internal and external validity\n+ MA/SR can improve **internal validity**\n    + e.g. aggregating improves power, so more likely to detect true effects\n+ but they might do this at the expense of reducing **external validity**\n    + e.g. our trial population might be more and more unlike our treatment population\n+ and reducing external validity might mean that an intervention might fail in ways that are hard to understand [@cartwright2012]\n\n![](images/05_exval.png){height=250}\n\n## Trial and treatment populations\n\n+ *wildly* dis-similar [@fortin2006]\n+ co-morbidity example\n    + a database of 980 general-practice patients were assessed against inclusion critera from 5 blood pressure RCTs\n    + of eligible patients \"89% to 100% had multiple chronic conditions\"\n        + mean numbers ranged from 5.5 ± 3.3 to 11.7 ± 5.3\n\n## Pragmatic trials\n\n![[@patsopoulos2011]](images/05_prago.png)\n\n## Final thought\n\n+ so there isn't going to be a simple answer about where on the precise / pragmatic spectrum we should end up\n    + it's an optimisation problem\n+ as EBM started by stressing the importance of explicit/judicious/conscientious use of evidence, we should probably adopt similar standards for our decision making in general\n    + explicit about the kind of q we're answering\n    + judicious about the way we use evidence to answer it\n    + conscientious in updating, revising, and checking our answers, and our methods\n\n\n## References",
    "supporting": [
      "ebm_05_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}